Supplementary Figure S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Holger N. Lode; Nikolai Siebert; Dominique Valteau‐Couanet; Alberto Garaventa; Adela Cañete; John W. Anderson; Isaac Yaniv; Shifra Ash; Juliet C. Gray; Thomas Klingebiel; Hans Loibner; Roberto Luksch; Carla Manzitti; Jean Michon; Cormac Owens; Ulrike Pötschger; Sascha Troschke‐Meurer; Evgenia Glogova; Ruth Ladenstein

doi:10.1158/1078-0432.30028889

Key Points

High-affinity fcgr2a and fcgr3a polymorphisms correlate with improved event-free survival in neuroblastoma patients, indicating potential genetic predictors.
Data shows patients with high-affinity fcgr variants experienced better overall survival rates during dinutuximab treatment in clinical trial.
Analysis of patient outcomes revealed significant differences in survival associated with fcgr polymorphisms, emphasizing the role of genetic factors.
Long-term infusion of dinutuximab likely enhances the impact of fcgr polymorphisms on survival outcomes in patients with high-risk neuroblastoma.

Implication

Analysis shows correlation between fcgr polymorphisms and overall survival in high-risk neuroblastoma, suggesting clinical implications.

Abstract

Supplementary Figure S4. Event-free survival and overall survival by high-affinity versus low-affinity FCGR2A (A and B) and FCGR3A (C and D) polymorphisms in the overall population. EFS, event-free survival; FCGR, Fc-gamma receptor polymorphisms; OS, overall survival; SE, standard error.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lode et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd028ff https://doi.org/10.1158/1078-0432.30028889

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers